AIkido Pharma (AIKI) Gets a Buy from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright maintained a Buy rating on AIkido Pharma (AIKIResearch Report), with a price target of $16.00. The company’s shares opened today at $4.30.

Bernardino covers the Healthcare sector, focusing on stocks such as Geron, Artelo Biosciences, and Cassava Sciences. According to TipRanks, Bernardino has an average return of 19.4% and a 32.49% success rate on recommended stocks.

AIkido Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $13.90 and a one-year low of $4.14. Currently, AIkido Pharma has an average volume of 84.07K.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AIKI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spherix, Inc. is a biotechnology development company, which engages in the provision of diversified commercialization platform for protected technologies. The firm’s activities include the acquisition and development of patents through internal or external research and development. Its patent portfolio consists of patents in the fields of wireless communications, satellite, solar and radio frequency, as well as 2 U.S. patents in pharmaceutical technology. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Read More on AIKI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More